Sanofi

Bruno Poirier

Philip Janiak

Dieter Kadereit

Paulus Wohlfart

Matthias Schaefer

Nicolas Baurin

Thomas Huebschle

Han Li

Dorothea Kominos

Alla Pritsker

Magali Mathieu

Alexey Rak

Francis Duffieux

Patrick Grailhe

Christopher Ryan Morgan

Cyril Daveu

Véronique Briand

Sabine Gratzer

Ashfaq Parkar

The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1), The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.

Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof

{4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of AKI (acute kidney injury). Medicament and pharmaceutical composition thereof.

{4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury

Growing community of inventors

Paris, France

Bruno Poirier